Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.
CRISPR Therapeutics AG reports developments in gene-based medicines built around CRISPR/Cas9 gene editing, cell therapy, in vivo editing and siRNA programs. Recurring updates cover CASGEVY, developed with Vertex for severe sickle cell disease and transfusion-dependent beta thalassemia, as well as pipeline work in cardiovascular disease, autoimmune disease, oncology, rare disease and Type 1 diabetes.
Company news also includes financial results, business updates, investor conference presentations, manufacturing and platform disclosures, collaborations such as Sirius Therapeutics, and capital actions involving common shares or convertible senior notes.
Avaí Bio (OTCQB: AVAI) is advancing cell-based therapies for diabetes and age-related conditions via joint ventures and licensed technologies. Its α-Klotho anti-aging program with Austrianova, through 50/50 JV Klothonova, will present new encapsulated cell data at the Second Annual Klotho Conference in September 2026.
The platform uses Austrianova’s Cell-in-a-Box® encapsulation to produce the longevity protein α-Klotho and to develop a bio-artificial pancreas for insulin-dependent diabetes, positioning Avaí Bio within the rapidly financed longevity-biotech sector.
CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 at 1:40 p.m. PDT. A live webcast will be available on the company's Investors "Events & Presentations" page, with a replay archived for 14 days.
CRISPR Therapeutics (Nasdaq: CRSP) reported Q1 2026 results and business progress on May 4, 2026. Key metrics: CASGEVY revenue $43.0M, >500 patients initiated, $2.44B cash (Mar 31, 2026) following $585.4M convertible notes issuance. Multiple in vivo IND/CTA advances, IND clearance for CTX310 U.S. expansion, clinical starts expected mid‑2026 for CTX460 and CTX340, and ongoing zugo‑cel trials across autoimmune and oncology indications.
R&D, G&A, and collaboration expenses moderated vs. prior year; net loss was $122.9M for Q1 2026. Several clinical and commercial milestones are expected in H2 2026.
CRISPR Therapeutics (Nasdaq: CRSP) will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 2:15 p.m. ET. A live webcast of the fireside chat will be available on the company’s Investors "Events & Presentations" page. A replay will be archived for 14 days.
CRISPR Therapeutics (Nasdaq: CRSP) priced an upsized private offering of $550 million aggregate principal amount of 2031 convertible senior notes, plus a $50 million initial purchaser option. Closing is expected on March 16, 2026.
The notes bear an effective coupon increased to 1.7308% to offset anticipated Swiss withholding, mature on March 1, 2031, and convert at 13.0617 shares per $1,000 (initial conversion price ~$76.56, ~45% premium to the March 10, 2026 share price). Estimated net proceeds are ~$536.3 million (or ~$585.2 million if option exercised).
CRISPR Therapeutics (Nasdaq: CRSP) announced a proposed private offering of $350 million aggregate principal amount of convertible senior notes due 2031, with an initial purchaser option of up to $52.5 million. Interest will accrue semiannually beginning September 1, 2026, and notes mature March 1, 2031. Upon conversion, the company will deliver common shares. The company intends to use net proceeds for general corporate purposes. Terms including interest rate and conversion rate will be set at pricing; the notes and shares will not be registered under the Securities Act.
CRISPR Therapeutics (Nasdaq: CRSP) reported Q4 and full‑year 2025 results and a broad business update on Feb 12, 2026. CASGEVY revenue was $54M in Q4 and $116M for 2025; 64 patients received infusions in 2025. Cash and equivalents totaled $1,975.8M at year‑end.
Pipeline progress includes in vivo liver editing (CTX310, CTX321), CTX460 planned trial mid‑2026, CTX340 planned H1 2026 start, siRNA collaboration updates in 2026, and zugo‑cel data advancing in autoimmune and oncology programs.
CRISPR Therapeutics (Nasdaq: CRSP) outlined 2026 strategic priorities and timing for multiple clinical and commercial milestones. The company enters 2026 with approximately $2 billion in cash, cash equivalents, and marketable securities and reported CASGEVY revenue exceeding $100M in 2025 with a nearly three-fold increase in patient initiations versus 2024. Key 2026 items include global CASGEVY commercialization and pediatric regulatory submissions in H1 2026, CTX310 and Lp(a) program updates in H2 2026, topline Phase 2 CTX611 data in H2 2026, and planned trial starts for CTX460 (mid-2026) and CTX340 (H1 2026). Multiple oncology, autoimmune, in vivo editing and siRNA programs advance through the clinic.
CRISPR Therapeutics (Nasdaq: CRSP) said members of its senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 8:15 a.m. PT in San Francisco.
A live webcast will be available on the company’s Events & Presentations page at https://crisprtx.gcs-web.com/events, and a replay will be archived on the company website for 14 days following the presentation.
CRISPR Therapeutics (Nasdaq: CRSP) provided a broad update on zugocaptagene geleucel (zugo-cel), an allogeneic anti-CD19 CAR T, across autoimmune diseases and B-cell malignancies on Dec 22, 2025. Key clinical readouts include deep B-cell depletion and drug-free DORIS remission through Month 6 in an SLE patient at the 100 million cell dose, and in R/R large B-cell lymphoma an ORR 90% and CRR 70% at the 600 million cell RP2D. Safety findings: Grade 3 CRS and ICANS each at 17% and serious infections 8% at the RP2D. A Phase 1 basket study in ITP and wAIHA has started and a collaboration with Lilly will evaluate zugo-cel plus pirtobrutinib. Additional data expected H2 2026.